Skip to main content
. Author manuscript; available in PMC: 2010 May 11.
Published in final edited form as: Radiother Oncol. 2009 Aug 6;93(2):307–310. doi: 10.1016/j.radonc.2009.06.032

Table 2.

Sigmoid, bladder and rectum EQD2 with an α/β = 3.

HDR LDR


Median Range Median Range
Sigmoid
D0.1cca 40.8 10.5–76.3 27.7 9–52
D0.1ccb 0.87 0.09–5.29 0.65 0.14–1.3
D0.1ccc 84.0 53.7–119.5 71.1 52.2–95.2
D2cca 25.3 7.8–36.5 22 7.6–42.9
D2ccb 0.53 0.06–2.6 0.53 0.11–0.99
D2ccc 68.3 51–79.7 65.9 50.8–86.1
Bladder
D0.1cca 53.3 18.1–98.8 53.8 17.5–81.5
D0.1ccb 1.12 0.11–4.03 1.18 0.33–2.04
D0.1ccc 96.5 61.3–142 97 60.7–124
D2cca 32.3 11.6–52.3 40.3 14.8–57.6
D2ccb 0.7 0.08–1.54 0.85 0.28–1.44
D2ccc 75.7 54.8–95.5 83.5 58.0–100.8
Rectum
D0.1cca 35.3 11–62.2 36 12–123.2
D0.1ccb 0.7 0.16–1.91 0.8 0.3–3.1
D0.1ccc 78.5 54.2–105.4 81.8 55.2–166.4
D2cca 20.6 7.2–40.8 27.5 10.1–83
D2ccb 0.42 0.02–1.53 0.6 0.25–2.1
D2ccc 63.8 50.4–84 72.5 53.3–126.2
a

Brachytherapy dose alone.

b

Ratio of delivered OAR brachytherapy dose to prescribed target dose.

c

External beam and brachytherapy dose.